AGENDA

Monday, November 7, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 PM</td>
<td>Welcome</td>
<td>Mark Ghobrial, MD, PhD, FACS, FRCS(Ed)</td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Introduction</td>
<td>Howard J. Huang, MD</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>STATE OF THE ART LECTURE: Surgical Advances in Lung Transplantation in 21st Century</td>
<td>Marcelo Cypel, MD, MSc, FACS, FRCSC</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>2:25 PM</td>
<td>Impact of the respiratory microbiome on acute and chronic lung diseases, and potential strategies for therapeutic targeting</td>
<td>Leopoldo Segal, MD</td>
</tr>
<tr>
<td>2:55 PM</td>
<td>Break and Exhibits</td>
<td></td>
</tr>
<tr>
<td>3:10 PM</td>
<td>The Role of Genetic Testing in Pulmonary Fibrosis</td>
<td>Janet Talbert, MS, CGC, LGC</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Tissue resident memory T cells in acute and chronic rejection after lung transplantation</td>
<td>Mark Snyder, MD</td>
</tr>
<tr>
<td>4:10 PM</td>
<td>Evolving landscape of CF therapy and its impact on lung transplantation</td>
<td>Stephen E. Kirkby, MD</td>
</tr>
<tr>
<td>4:40 PM</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

FACULTY

COURSE DIRECTOR

R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed)

J.C. Walter Jr. Presidential Distinguished Chair
Director, J.C. Walter Jr. Transplant Center
Director, Transplantation Research
Chief, Division of Transplantation, Department of Surgery
Professor of Surgery
Weill Cornell Medical College
Houston Methodist

MODERATOR

Howard J. Huang, MD

Chief, Pulmonary, Critical Care and Sleep Medicine
Chief, Section of Lung Transplantation
Medical Director, Houston Methodist
Lung Transplant Center
Houston Methodist Hospital
**GUEST FACULTY**

**Marcelo Cypel MD, MSc, FACS, FRCSC**

Surgical Director Ajmera Transplant Centre at UHN  
Surgical Director UHN ECLS Program  
Canada Research Chair in Lung Transplantation  
Professor of Surgery, Division of Thoracic Surgery  
University of Toronto, University Health Network  
Senior-Scientist, Toronto General Research Institute  
Toronto General Hospital, MaRS Centre, West Tower

**Stephen E. Kirkby, MD**

Pulmonary & Critical Care Medicine  
OSU Lung Transplant Program  
The Ohio State University

**Leopoldo N. Segal, MD**

William Rom and David Kamelhar Associate Professor of Medicine  
Director of the NYU Langone Translational Lung Biology Laboratory  
Associate Division Director for Research  
Division of Pulmonary and Critical Care Medicine  
New York University School of Medicine  
NYU Langone Health

**Mark E. Snyder, MD**

Pulmonary, Allergy and Critical Care Medicine  
Assistant Professor of Medicine  
Member, Graduate Program in Microbiology and Immunology

**Janet Talbert, MS, CGC, LGC**

Genetic Counselor, Associate in Pediatrics  
Division of Medical Genetics and Genomic Medicine  
Department of Pediatrics  
Vanderbilt University Medical Center
New Insights in Advanced Lung Diseases and Lung Transplantation  
Monday, November 7, 2022 | Hybrid Symposium

PROGRAM OVERVIEW
The Houston Methodist J.C. Walter Jr. Transplant Center is proud to introduce its leading educational event of the year. This program is designed to provide an innovative view on strategies for the widespread issues of organ failure management. Renowned national and international speakers will share their state-of-the-art techniques and advanced research to educate attendees on the advancements of organ failure management.

TARGET AUDIENCE
The George P. Noon Conference Series is designed for nephrologists, cardiologists, gastroenterologists, hepatologists, pulmonologists, pathologists, internists, oncologists, physicians treating patients with organ failure, nurses, family practitioners, social workers and allied health professionals with an interest in organ failure transplant management.

EDUCATIONAL OBJECTIVES
Upon completion of this course, the participant should be able to:
• Describe surgical advances in lung transplantation in the 21st Century
• Explain the impact of the respiratory microbiome on acute and chronic lung diseases with potential strategies for Therapeutic Targeting
• Interpret the role of genetic testing in pulmonary fibrosis
• Discuss the evolving landscape of Cystic Fibrosis Therapy and its impact on lung transplant

NURSING OUTCOMES STATEMENT
Nurses attending this activity will be better prepared to provide high quality care based on an enriched understanding of current research, emerging treatments and procedures related to advanced lung disease and transplantation. They will be able to identify at least one new learning they can put into their personal practice related to management of advanced lung disease and transplantation.

EDUCATION METHODS
Didactic lectures, panel discussion

EVALUATION METHOD
Evaluation by questionnaire will address program content, presentation, and possible bias.

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
Physicians
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Houston Methodist will provide up to 3.33 contact hours for this activity. Participants must attend each session in its entirety and complete the corresponding items on the evaluation tool.

Transplant Coordinators
This course has been approved by the American Board for Transplant Certification for 3.25 Category I CEPTCs.
Social Workers
Houston Methodist and J.C. Walter Jr. Transplant Center designate this activity for 3.0 CEU for social work. This offering complies with section 781.509 of the rules of the Texas State Board of Social Work Examiners.

HOW TO RECEIVE YOUR CERTIFICATE
Physicians
An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

Nurses
To be awarded up to 3.33 contact hours for this continuing education activity, the participant must:
- Be sure to check in and complete the sign in process
- Attend each session in its entirety (Contact hours are awarded only for full day attendance)
- Complete the evaluation tool. An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

DISCLAIMER AND DISCLOSURES
Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.
Disclosures continued

All the relevant financial relationships listed for these individuals have been mitigated.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Relevant Financial Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcelo Cypel MD, MSc, FACS, FRCSC</td>
<td>Speaker</td>
<td>Consultant: Lung Bioengineering; Shareholder: Traferox Technologies Inc.</td>
</tr>
<tr>
<td>Leopoldo N. Segal, MD</td>
<td>Speaker</td>
<td>Adjudication of Events: Sanofi</td>
</tr>
</tbody>
</table>

All other individuals in control of content of this activity have no relevant financial relationships with ineligible companies to disclose.

EXHIBITORS

We gratefully acknowledge the following companies for participating as exhibitors at this activity:

Astellas
Boehringer-Ingelheim
CareDx
Mallinckrodt
Norah’s Home
Takeda
Veloxis